ASCO 2023
ASCO 2023
American Society of Clinical Oncology 2023 Annual Meeting
Advertisement
Ajitha Kommalapati, MDASCO 2023 | August 15, 2023
Dr. Kommalapati shares her thoughts on the association between tumor-informed MRD and clinical outcomes for MIBC.
View More
Shilpa Gupta, MDASCO 2023 | August 4, 2023
Drs. Shilpa Gupta and Vadim Koshkin continue on the EV-103 trial with reference to outcomes and toxicities in cohort K.
Shilpa Gupta, MDASCO 2023 | August 31, 2023
Drs. Shilpa Gupta and Vadim Koshkin discuss the EV-103 trial and data, including long-term results for cohort A.
Tanya JindalASCO 2023 | July 28, 2023
Tanya Jindal expands upon the UNITE study findings relative to biomarkers of response for SG and EV for advanced UC.
Thomas Hutson, DO, PharmD, FACPASCO 2023 | July 17, 2023
Dr. Hutson details the latest 4-year CLEAR data for patients who received 1L lenvatinib plus pembrolizumab for advanced RCC.
Thomas Hutson, DO, PharmD, FACPASCO 2023 | July 17, 2023
Dr. Hutson provides an overview of different combination therapies used and investigated for first-line advanced RCC.
Alberto Bossi, MDASCO 2023 | August 23, 2023
Drs. Bossi and Wallis conclude with a breakdown of the right patients for radiotherapy when presenting with de novo mCSPC.
Alberto Bossi, MDASCO 2023 | August 23, 2023
Drs. Bossi, Wallis address which patients with mCSPC experience synergistic effects from abiraterone plus radiotherapy.
Alberto Bossi, MDASCO 2023 | August 23, 2023
Drs. Bossi and Wallis break down the results of the PEACE-1 study presented as an LBA at the ASCO Annual Meeting.
Laurence Albiges, MD, PhDASCO 2023 | August 1, 2023
Dr. Albiges details the KEYMAKER-U03B study, outcomes for patients in arm B5, and next lines of research for belzutifan.
Yohann Loriot, MD, PhDASCO 2023 | August 1, 2023
Drs. Loriot, Koshkin summarize erdafitinib versus chemotherapy in patients with advanced UC with select FGFR alterations.
Chung-Han Lee, MD, PhDASCO 2023 | August 23, 2023
Drs. Lee and McKay discuss the latest data on KEYNOTE-B61 for first-line lenvatinib plus pembrolizumab for nccRCC.
Benjamin Miron, MDASCO 2023 | June 16, 2023
Dr. Miron provides an overview of clinical implications of molecular alterations in intraductal carcinoma of the prostate.
Thomas Powles, MBBS, MRCP, MDASCO 2023 | June 15, 2023
Drs. Powles and Koshkin break down the Q-TWiST analysis conducted on the JAVELIN Bladder 100 study for advanced UC.
Seth Lerner, MD, FACSASCO 2023 | June 20, 2023
Drs. Lerner and Koshkin explain the implications of the latest data from the SWOG S1011 study for mUC.
Terence Friedlander, MDASCO 2023 | June 15, 2023
Drs. Friedlander and Koshkin highlight the 18-month data from the EV-103 study on EV/pembro first-line mUC treatment.
Arlene O. Siefker-Radtke, MDASCO 2023 | June 15, 2023
Drs. Siefker-Radtke and Koshkin detail the NORSE study design, results, and implications for treating patients with mUC.
Karim Fizazi, MD, PhDASCO 2023 | August 1, 2023
Drs. Fizazi and Wallis detail the latest updates regarding TALAPRO-2 for patients with mCRPC and HRR gene alterations.
Brian Rini, MD, FASCOASCO 2023 | June 5, 2023
Drs. Rini and Wallis discuss the results of a late-breaking abstract on KEYNOTE-426, which now has long-term survival data.
Oncology BrothersASCO 2023 | June 6, 2023
The Oncology Brothers chat with Dr. Wallis on PARP inhibitors as well as neoadjuvant IO and EV for bladder cancer.
Advertisement
Advertisement
Advertisement